The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine
The concept of innovative drugs fluctuated and surged in the afternoon, with Nossan reaching a 20% limit up, and PR, Tigermed, Jiuzhou Pharma, and Highfine following suit